Navigation Links
Bronchial Thermoplasty: Boon to Severe Asthma Patients?

Encouraging results for the use of bronchial thermoplasty procedure were reported by the Research in Severe Asthma (RISA) Trial , at the annual scientific assembly of the American Thoracic Society (ATS) by Neil Thomson,MD, Professor of Respiratory Medicine, University of Glasgow, Scotland. This announcement came from Asthmatx, Inc., a medical device company that has developed a catheter-based procedure for the treatment of asthma.

Severe asthma patients who underwent bronchial thermoplasty showed significant improvements in asthma control, pulmonary function and quality of life. There was also lesser use of rescue medications. The novel, non-drug procedure is under clinical investigation in the United States.

The RISA Trial was conducted at a total of eight hospitals, in three countries, and evaluated the safety and efficacy of bronchial thermoplasty in 32 adult subjects with severe persistent asthma who remained symptomatic despite taking regular asthma medications.

Compared to patients who received only standard asthma medications, patients who received the bronchial thermoplasty procedure and standard medications showed clinically and statistically significant improvements in pulmonary function, quality of life, and asthma control, and used less rescue medication nearly 6 months following the procedure.

One year following the treatment, 50% of bronchial thermoplasty treated patients were able to wean completely off oral corticosteroids (OCS), compared to 14% of patients who did not receive the treatment. Further, a greater overall reduction in OCS dose was observed at 52 weeks in the bronchial thermoplasty treated patients compared with those that did not receive treatment at 52 weeks, although this difference didnt reach statistical significance. The study was not powered to show statistical significance in medication changes.

In this group of patients with severe asthma, an increase in respi ratory-related symptoms, and hospitalizations related to these symptoms, were expected and observed during the period immediately following the procedure. These symptoms were of the type expected following bronchoscopy in patients with asthma, and they resolved on average within seven days.

"Following bronchial thermoplasty, patients with severe, refractory asthma demonstrated significant improvements in pulmonary function and asthma control," states Dr. Thomson. "These significant and seemingly long-lasting improvements came at the cost of a short-term increase in hospitalizations, but the apparent benefits seem to be greater than the manageable consequences of the procedure."

"The results from this randomized, controlled, multi-center trial provide some hope for patients with severe, refractory asthma people who despite taking state-of-the-art medications are still experiencing the disruptive and distressing symptoms of their asthma," states Glen French, CEO of Asthmatx, Inc. "We were particularly encouraged by the data that suggested that patients may be able to reduce their oral steroid dose and still maintain their asthma control."


'"/>




Related medicine news :

1. New Drug for Bronchial Asthma
2. Bronchial thermoplasty – a promising treatment for asthmatic
3. Low Cholesterol Linked to Severe Depression and Violent Behavior in Men
4. Severe stress weakens immunity
5. Severe Acute respiratory Syndrome (SARS)
6. WHO Travel Advice to prevent spread of "Severe Acute Respiratory Syndrome (SARS)
7. Patients With Severe Hemophilia At Risk Of Developing Osteoporosis
8. Severe sleep apnea can cause liver problems
9. Scientists Unveil Mechanism Behind Resistance to Severe Malaria
10. Strong Magnetic Stimulation Can Help Treating Severe Depression
11. Patients Suffering From Severe Mental Diseases Are At Risk Of Being Crime Victims
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/9/2016)... ... December 09, 2016 , ... Flottman Company is a ... As a means of expanding capabilities Flottman has added a G&K Vijuk TTM ... professional inserts (PIs) and patient package inserts (PPIs) that will marry with all ...
(Date:12/9/2016)... ... December 09, 2016 , ... The Justin Veatch Fund ... (NCADD) is recommending the film Whispering Spirits and its discussion guide ... Columbia as an education tool in the war against teen drug abuse. NCADD ...
(Date:12/9/2016)... ... ... An inventor from Cana, Va., wanted to fulfill the need for a device ... The patent-pending SAFETY STRAP FOR AMPUTEES improves accessibility. It eliminates discrimination. It is also ... a matter of minutes, or even seconds. The SAFETY STRAP FOR AMPUTEES is a ...
(Date:12/9/2016)... Fort Lee, NJ (PRWEB) , ... December 09, ... ... the 2016 Founders Ball at The Pierre Hotel in New York, NY, on ... 700 friends, benefactors, dignitaries and physicians attended the annual event, which raised over ...
(Date:12/9/2016)... , ... December 09, 2016 , ... "I had a ... inventor from Winchester, Va. "I thought that if the nebulizer had a more child-friendly ... than fearing them." , He developed the patent-pending NEBY to avoid the need to ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... , Dec 9, 2016 Research and ... Market 2016-2020" report to their offering. ... The global travel vaccines market to ... The report covers the present scenario and the growth prospects ... market size, the report considers the revenue generated from the sales ...
(Date:12/8/2016)... MOUNTAIN VIEW, Calif. , Dec. 8, 2016 ... it intends to offer newly issued shares of common stock, ... "Shares") pursuant to an underwritten public offering.  The final terms ... at the time of pricing, and there can be no ... completed. IRIDEX expects to use the net proceeds ...
(Date:12/8/2016)... LONDON , Dec. 8, 2016  The global ... of 8.8% during the forecast period of 2016 to ... billion by 2021 from USD 18.21 billion in 2016. ... surgeries, rising incidences of sports related injuries and spinal ... and rising need of effective blood loss management. ...
Breaking Medicine Technology: